Shanghai Ruiliyuan Biotechnology Co., Ltd.
Shanghai, Shanghai Municipality
What changed
Phase I trial registered: hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
3mo agoTrial registeredApr 16, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 69 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase I
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE1 registered
Jun 1, 2026Acute Graft Versus Host Disease · WITHDRAWN · sponsor: Nanfang Hospital, Southern Medical University · hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation
ClinicalTrials.gov · NCT06444022 (opens the source filing in a new tab)
- Trial
PHASE1 registered
Oct 17, 2024Hepatic Cell Carcinoma · RECRUITING · sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. · HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
ClinicalTrials.gov · NCT06515314 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources